Brokerages Set Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target at $44.25

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $44.25.

Several analysts have issued reports on DMRA shares. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price on the stock. Guggenheim restated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Finally, Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research report on Friday, January 9th.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $40,000. Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $266,000. Virtu Financial LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth $49,000. Sigma Planning Corp acquired a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $334,000. Finally, Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $76,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ:DMRA opened at $25.09 on Friday. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -2.07 and a beta of 1.59. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.01 and a 12 month high of $38.33. The stock’s 50 day moving average price is $26.81 and its 200 day moving average price is $20.27.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.